X0303 4 2010-12-06 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001476860 Wells William McDowall C/O 7150 MISSISSAUGA ROAD MISSISSAUGA A6 L5N 8M5 ONTARIO, CANADA 1 0 0 0 Common Stock, no par value 2010-12-06 4 S 0 490461 28.13 D 75000 D Common Stock, no par value 2010-12-07 4 M 0 19540 0 A 94540 D Common Stock, no par value 2010-12-07 4 F 0 2150 26.12 D 92390 D Common Stock, no par value 2010-12-07 4 S 0 17390 28.05 D 75000 D Restricted Share Units 2010-12-07 4 M 0 19540 0 D 2010-11-08 2013-02-17 Common Stock, no par value 19540 0 D The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.29, inclusive. The reporting person undertakes to provide to Valeant Pharmaceuticals International, Inc. ("Valeant"), any shareholder of Valeant, or the staff of the Securities and Exchange Commission, in each case upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Common shares withheld from the issuance of common shares to the Reporting Person to satisfy the tax withholding obligations due upon vesting of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one common share, no par value, of Valeant. The RSUs accelerated in connection with the merger between the issuer (formerly known as Biovail Corporation) and Valeant Pharmaceuticals International and vested following the completion of the issuer's blackout period restrictions on November 8, 2010. By: Angie Palmer for: William Wells 2010-12-08